6533b822fe1ef96bd127cd28

RESEARCH PRODUCT

Different patterns of in vivo pro-oxidant states in a set of cancer- or aging-related genetic diseases

Giovanni PaganoFrank J. KellyMarco D'ischiaPaolo DeganChristina DunsterRita CalzoneAna LloretFederico V. PallardóPaola ManiniAdriana Zatterale

subject

AdultMalemedicine.medical_specialtyDown syndromeXeroderma pigmentosumAdolescentmedicine.disease_causeBiochemistrychemistry.chemical_compoundAtaxia TelangiectasiaPhysiology (medical)Internal medicinemedicineHumansBloom syndromeChildAgedXeroderma PigmentosumMethylglyoxalDeoxyguanosineGlutathioneGlyoxalMiddle AgedAscorbic acidmedicine.diseasePyruvaldehydeGlutathioneEndocrinologyFanconi AnemiaantioxidantschemistryBiochemistry8-Hydroxy-2'-DeoxyguanosineUric acidOxidative streFemaleWerner SyndromeDown SyndromeReactive Oxygen SpeciesOxidative stressBloom SyndromeDNA Damage

description

A comparative evaluation is reported of pro-oxidant states in 82 patients with ataxia telangectasia (AT), Bloom syndrome (BS), Down syndrome (DS), Fanconi anemia (FA), Werner syndrome (WS), and xeroderma pigmentosum (XP) vs 98 control donors. These disorders display cancer proneness, and/or early aging, and/or other clinical features. The measured analytes were: (a) leukocyte and urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), (b) blood glutathione (GSSG and GSH), (c) plasma glyoxal (Glx) and methylglyoxal (MGlx), and (d) some plasma antioxidants [uric acid (UA) and ascorbic acid (AA)]. Leukocyte 8-OHdG levels ranked as follows: WS>BS approximately FA approximately XP>DS approximately AT approximately controls. Urinary 8-OHdG levels were significantly increased in a total of 22 patients with BS, FA, or XP vs 47 controls. The GSSG:GSH ratio was significantly increased in patients with WS and in young (< or =15 years) patients with DS or with FA and decreased in older patients with DS or FA and in AT, BS, and XP patients. The plasma levels of Glx and/or MGlx were significantly increased in patients with WS, FA, and DS. The UA and AA levels were significantly increased in WS and DS patients, but not in AT, FA, BS, nor XP patients. Rationale for chemoprevention trials is discussed.

10.1016/j.freeradbiomed.2007.10.046https://hdl.handle.net/11384/84256